RecruitingPhase 1NCT05279300
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CStone Pharmaceuticals
- Intervention
- CS5001(drug)
- Enrollment
- 480 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- North Shore Hematology Oncology Associates, East Setauket, New York, United States
- Columbia U. - Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- BUMC - Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
- Scientia Clinical Research Limited, Randwick, New South Wales, Australia
- Ashford Cancer Centre Research, Adelaide, South Australia, Australia
- Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia
- Royal Adelaide Hospital (RAH), Adelaide, South Australia, Australia
- Epworth Freemasons Medical Centre, East Melbourne, Victoria, Australia
- Epworth Foundation trading as Epworth HealthCare, Melbourne, Victoria, Australia
- Anhui Provincial Cancer Hospital, Hefei, Anhui, China
- Anhui Provincial Hospital,, Hefei, Anhui, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Yanda Lu Dao Pei Hospital, Beijing, Beijing Municipality, China
- The Cancer Hospital Affiliated to Chongqing University, Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05279300 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation